BeiGene's 2025 Q1 Earnings Call: Unpacking Contradictions in CDK4, BRUKINSA, and R&D Strategies

CDK4 program and BRUKINSA's role in breast cancer and autoimmune diseases, BRUKINSA's potential impact and market position, commercial strategy and pricing in China, R&D and clinical trial strategy are the key contradictions discussed in BeiGene's latest 2025Q1 earnings call.



Revenue Growth and Pipeline Progress:
- BeiGene reported first quarter 2025 revenue of $1.1 billion, up 49% year-on-year.
- This growth was driven by the strong performance of key brands like BRUKINSA and TEVIMBRA, as well as rapid progress in the company's internal pipeline.

clinical development and Approvals:
- The company achieved significant milestones with sonro, having completed enrollment in the Phase III CELESTIAL trial and submitted regulatory filings in China.
- This progress is crucial for establishing sonro as a potential game-changer in multiple B-cell malignancies.

Commercial Expansion and Market Share:
- In the U.S., BRUKINSA's Q1 sales reached $563 million, marking a 60% year-over-year increase.
- This growth was driven by BRUKINSA's leadership in new patient starts and strong demand in the BTK inhibitor market.

Supply Chain Resiliency and Global Manufacturing:
- BeiGene emphasized its commitment to regional manufacturing, with a $800 million investment in a Hopewell, New Jersey facility.
- This investment is part of the company's strategy to mitigate risks from trade policies and tariffs, ensuring reliable supply and operational continuity.